Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU1 | Q99519 | 18/20 | 1.00 |
| ▸ | NEU2 | Q9Y3R4 | 14/20 | 1.00 |
| ▸ | NEU3 | Q9UQ49 | 5/20 | 0.86 |
| ▸ | NEU4 | Q8WWR8 | 3/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22276949 | 1.00 | NEU1 (1.00) | NEU1NEU2NEU3NEU4 | |
| SCHEMBL20568929 | 1.00 | NEU1 (1.00) | NEU1NEU2NEU3NEU4 | |
| SCHEMBL22276973 | 0.99 | NEU1 (1.00) | NEU1NEU2NEU3NEU4 | |
| SCHEMBL20568067 | 0.99 | NEU1 (1.00) | NEU1NEU2NEU3NEU4 | |
| SCHEMBL22276974 | 0.99 | NEU1 (1.00) | NEU1NEU2NEU3NEU4 | |
| SCHEMBL22276978 | 0.97 | NEU1 (1.00) | NEU1NEU2NEU3NEU4 | |
| SCHEMBL22276979 | 0.97 | NEU1 (1.00) | NEU1NEU2NEU3NEU4 | |
| SCHEMBL20568072 | 0.92 | NEU1 (1.00) | NEU1NEU2NEU3NEU4 | |
| SCHEMBL22276947 | 0.92 | NEU1 (1.00) | NEU1NEU2NEU3NEU4 | |
| SCHEMBL22276948 | 0.92 | NEU1 (1.00) | NEU1NEU2NEU3NEU4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773129-B2 | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-10-03 | — | — | US | disclosed |
| US-20200239512-A1 | METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239512-A1 | METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE | NEU1, NEU3, NEU2 | NEU1 1/4885NEU2 3/4885NEU3 2/4885 |
| US-11773129-B2 | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase | NEU1, NEU3, NEU2 | NEU1 1/4885NEU2 3/4885NEU3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.